Common use of Consequence of No Sales Clause in Contracts

Consequence of No Sales. 5.5.1 In addition to the terms of Section 5.4, Hana shall be deemed to have breached its obligation to use Commercially Reasonable Efforts in conducting marketing of a Product in any country in the Major Markets if, for a continuous period of one hundred and eighty (180) days at any time following launch of commercial sales of the Product in any such country in the Major Markets, no sales of the Product are made in the ordinary course of business in such country by Hana, an Affiliate, a Licensee or a Sublicensee, unless: (a) The Parties mutually agree it is to their mutual benefit to delay commercial sales of Product in such country; or (b) Hana is prevented, restricted, interfered with or delayed in making such sales by reason of a cause beyond Hana’s reasonable control and can demonstrate same to INEX; in which event such period shall be extended by (i) the period of delay mutually agreed upon or (ii) by the period of Hana’s inability, provided that Hana uses its Commercially Reasonable Efforts to avoid or remove the cause of such inability. 5.5.2 If Hana breaches its obligation set forth in Section 5.5.1: (a) INEX shall be entitled to terminate all rights granted to Hana in the Definitive Agreements in respect of each such Product in such country in the Major Markets by written notice to Hana in the event that Hana is in default of its obligations under Section 5.5.1 and fails to remedy such default within sixty (60) days after notice thereof by INEX; (b) All Licenses and Sublicenses granted by Hana in respect of such Product in such country in the Major Markets shall forthwith terminate upon the effective date of termination in Section 5.5.2(a); and (c) Hana shall continue to be bound by and shall comply with Sections 14.6, 14.8, and any other Sections which are intended to survive any termination of rights under this Agreement.

Appears in 3 contracts

Samples: License Agreement, License Agreement (TEKMIRA PHARMACEUTICALS Corp), License Agreement (Tekmira Pharmaceuticals Corp)

AutoNDA by SimpleDocs

Consequence of No Sales. 5.5.1 (a) In addition to the terms of Section 5.410.3, Hana shall be deemed to have breached its obligation to use Commercially Reasonable Efforts in conducting marketing of a Product in any country in the Major Markets if, for a continuous period of one hundred and eighty (180) days at any time following launch of commercial sales of the Product in any such country in the Major Markets, no sales of the Product are made in the ordinary course of business in such country by Hana, an Affiliate, a Licensee Affiliate or a Sublicensee, unless: (ai) The the Parties mutually agree it is to their mutual benefit to delay commercial sales of Product in such country; or (bii) Hana is prevented, restricted, interfered with or delayed in making such sales by reason of a cause beyond Hana’s reasonable control and can demonstrate same to INEX; in which event such period shall be extended by (i) the period of delay mutually agreed upon or (ii) by the period of Hana’s inability, provided that Hana uses its Commercially Reasonable Efforts to avoid or remove the cause of such inability. 5.5.2 (b) If Hana breaches its obligation set forth in Section 5.5.1:10.4(a): (ai) INEX shall be entitled to terminate all rights granted to Hana in the Definitive Agreements in respect of each such Product in such country in the Major Markets by written notice to Hana in the event that Hana is in default of its obligations under Section 5.5.1 10.4(a) and fails to remedy such default within sixty (60) days after notice thereof by INEX; (bii) All Licenses and Sublicenses sublicenses granted by Hana in respect of such Product in such country in the Major Markets shall forthwith terminate upon the effective date of termination in Section 5.5.2(a10.4(b)(i); and (ciii) Hana shall continue to be bound by and shall comply with Sections 14.617.6, 14.8, 17.7 and any other Sections which are intended to survive any termination of rights under this Agreement.

Appears in 1 contract

Samples: Sublicense Agreement (Hana Biosciences Inc)

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!